Maternal Immune Response to ZIKV Triggers High-Inflammatory Profile in Congenital Zika Syndrome

Viruses. 2023 Jan 13;15(1):220. doi: 10.3390/v15010220.

Abstract

The immunological mechanisms involved in the development of congenital Zika syndrome (CZS) have yet to be fully clarified. This study aims to assess the immuno-inflammatory profile of mothers and their children who have been diagnosed with CZS. Blood samples, which were confirmed clinically using the plaque reduction neutralization test (PRNT), were collected from children with CZS and their mothers (CZS+ group). Samples were also collected from children who did not develop CZS and had a negative PRNT result and from their mothers (CZS- group). The data demonstrated a correlation between the leukocyte profile of CZS+ children and their mothers, more evident in monocytes. Monocytes from mothers of CZS+ children showed low expression of HLA and elevated hydrogen peroxide production. CZS+ children presented standard HLA expression and a higher hydrogen peroxide concentration than CZS- children. Monocyte superoxide dismutase activity remained functional. Moreover, when assessing the monocyte polarization, it was observed that there was no difference in nitrite concentrations; however, there was a decrease in arginase activity in CZS+ children. These data suggest that ZIKV infection induces a maternal immuno-inflammatory background related to the child's inflammatory response after birth, possibly affecting the development and progression of congenital Zika syndrome.

Keywords: Zika virus infection; microcephaly; monocytes; reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brazil
  • Child
  • Female
  • Humans
  • Hydrogen Peroxide
  • Immunity
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • Zika Virus Infection* / diagnosis
  • Zika Virus*

Substances

  • Hydrogen Peroxide

Grants and funding

This work was supported by: Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior—Brasil (CAPES—process 88881.130813/2016-01—FINANCE CODE 001); Conselho Nacional de Desenvolvimento e Pesquisa (CNPq—Process: 440573/2016-5); Fundação de Amparo a Pesquisa do Maranhão (FAPEMA—Process: 008/2016).